# MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)

> **NCT02949908** · — · TERMINATED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 2 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Rebif

## Key facts

- **NCT ID:** NCT02949908
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-09
- **Primary completion:** 2017-08-25
- **Final completion:** 2017-08-25
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Delay in site selection and recruitment.
- **Last updated:** 2019-01-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02949908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02949908, "MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02949908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*